CERUS CORP Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by CERUS CORPORATION on December 9, 2024. The report discloses the entry into a material definitive agreement regarding the company's supply chain operations.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual agreement and does not contain financial statement data.
Material Changes
On December 9, 2024, the Company entered into the Second Amended and Restated Supply and Manufacturing Agreement (the "2025 Agreement") with Porex Corporation. Key terms include:
- Effective Date: January 1, 2025.
- Term Extension: Extends the current agreement term through December 31, 2027.
- Pricing Structure: Unit pricing for platelet wafers and plasma disks is fixed for the first 24 months (starting January 1, 2025), transitioning to volume-based pricing thereafter.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or specific risk factors beyond the standard disclosure that the summary is qualified by the full text of the agreement. The full text of the 2025 Agreement is intended to be filed as an exhibit to the Company's Annual Report on Form 10-K for the fiscal year ending December 31, 2024.
Investor Verification Checklist
- Verify the specific unit pricing amounts for platelet wafers and plasma disks in the full 2025 Agreement once filed.
- Review the volume-based pricing thresholds and formulas applicable after the initial 24-month period.
- Confirm the total estimated cost impact of the extended term through 2027 relative to the prior agreement.
- Monitor the upcoming Form 10-K filing for the complete text of the agreement.